{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T04:09:16Z","timestamp":1751083756765,"version":"3.41.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,9,1]],"date-time":"2001-09-01T00:00:00Z","timestamp":999302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2001,9]]},"DOI":"10.1023\/a:1013393607384","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T21:46:14Z","timestamp":1040679974000},"page":"423-436","source":"Crossref","is-referenced-by-count":0,"title":["Antiplatelet Therapy in Acute Coronary Syndromes without Persistent ST-Segment Elevation"],"prefix":"10.1007","volume":"15","author":[{"given":"Deepak","family":"Jain","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo A.","family":"Katus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Richardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"388387_CR1","first-page":"3","volume-title":"Cardiovascular Thrombosis","author":"LA Harker","year":"1998","unstructured":"Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular Thrombosis, 2nd ed. Philadelphia: Lippincot-Raven, 1998: 3-22.","edition":"2nd ed."},{"key":"388387_CR2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJM199506083322306","volume":"332","author":"J Lefkovits","year":"1995","unstructured":"Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb\/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-1559.","journal-title":"N Engl J Med"},{"key":"388387_CR3","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0092-8674(87)90233-9","volume":"48","author":"RO. Hynes","year":"1987","unstructured":"Hynes RO. Integrins:Afamily of cell surface receptors. Cell 1987; 48: 549-554.","journal-title":"Cell"},{"key":"388387_CR4","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1055\/s-2007-1002571","volume":"18","author":"EF Plow","year":"1992","unstructured":"Plow EF, D'souza SE, Ginsberg MH. Ligand binding to GP IIb-IIIa: A status report. Semin Thromb Hemost 1992; 18: 324-332.","journal-title":"Semin Thromb Hemost"},{"key":"388387_CR5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/med.2610140203","volume":"14","author":"D Cox","year":"1994","unstructured":"Cox D, Aoki T, Seki J, Motoyama Y, Yoshida K. The pharmacology of the integrins. Med Res Rev 1994; 14: 195-228.","journal-title":"Med Res Rev"},{"key":"388387_CR6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/09537109309013225","volume":"4","author":"K. Schror","year":"1993","unstructured":"Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993; 4: 252-261.","journal-title":"Platelets"},{"key":"388387_CR7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/s-0038-1642389","volume":"71","author":"M Cattaneo","year":"1994","unstructured":"Cattaneo M, Akkawat B, Kinlough-Rathbone RL, Packham MA, Cimminiello C, Mannucci PM. Ticlopidine facilitates the deaggregation of human platelets aggregated by thrombin. Thromb Haemost 1994; 71: 91-94.","journal-title":"Thromb Haemost"},{"key":"388387_CR8","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1161\/01.ATV.12.4.430","volume":"12","author":"DC Mills","year":"1992","unstructured":"Mills DC, Puri R, Hu CJ, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12: 430-436.","journal-title":"Arterioscler Thromb"},{"key":"388387_CR9","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200006153422402","volume":"342","author":"CL Bennett","year":"2000","unstructured":"Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342: 1773-1777.","journal-title":"N Engl J Med"},{"key":"388387_CR10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","volume":"348","author":"CAPRIE Steering Committee.","year":"1996","unstructured":"CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.","journal-title":"Lancet"},{"key":"388387_CR11","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-0038-1656351","volume":"68","author":"C Weber","year":"1992","unstructured":"Weber C, Beetens JR, Tegtmeier F, et al. Ridogrel inhibits systemic and renal formation of thromboxane A2 and antagonizes platelet thromboxane A2\/prostaglandin endoperoxide receptors upon chronic administration to man. Thromb Haemost 1992; 68: 214-220.","journal-title":"Thromb Haemost"},{"key":"388387_CR12","doi-asserted-by":"crossref","first-page":"S715","DOI":"10.1378\/chest.114.5_Supplement.715S","volume":"114","author":"JI Weitz","year":"1998","unstructured":"Weitz JI, Hirsh J. New antithrombotic agents. Chest 1998; 114: S715-727.","journal-title":"Chest"},{"key":"388387_CR13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","volume":"330","author":"The EPIC Investigators.","year":"1994","unstructured":"The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-961.","journal-title":"N Engl J Med"},{"key":"388387_CR14","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(94)90007-8","volume":"343","author":"EJ Topol","year":"1994","unstructured":"Topol EJ, Califf RM, Weisman HF, et al. Randomised trial of coronary intervention with antibody against platelet IIb\/IIIa integrin for reduction of clinical restenosis: Results at six months. The EPIC Investigators. Lancet 1994; 343: 881-886.","journal-title":"Lancet"},{"key":"388387_CR15","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1997.03550060055036","volume":"278","author":"EJ Topol","year":"1997","unstructured":"Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb\/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278: 479-484.","journal-title":"JAMA"},{"key":"388387_CR16","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S0735-1097(97)00110-1","volume":"30","author":"AM Lincoff","year":"1997","unstructured":"Lincoff AM, Califf RM, Anderson KM, et al. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb\/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. J Am Coll Cardiol 1997; 30: 149-156.","journal-title":"J Am Coll Cardiol"},{"key":"388387_CR17","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0002-9149(96)00128-2","volume":"77","author":"J Lefkovits","year":"1996","unstructured":"Lefkovits J, Ivanhoe RJ, Califf RM, et al. Effects of platelet glycoprotein IIb\/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. EPIC investigators. Am J Cardiol 1996; 77: 1045-1051.","journal-title":"Am J Cardiol"},{"key":"388387_CR18","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","volume":"336","author":"The EPILOG Investigators.","year":"1997","unstructured":"The EPILOG Investigators. Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-1696.","journal-title":"N Engl J Med"},{"key":"388387_CR19","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","volume":"349","author":"The IMPACT-II Investigators.","year":"1997","unstructured":"The IMPACT-II Investigators. Randomised placebocontrolled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-1428.","journal-title":"Lancet"},{"key":"388387_CR20","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","volume":"349","author":"The CAPTURE Investigators.","year":"1997","unstructured":"The CAPTURE Investigators. Randomised placebocontrolled trial of abciximab before and during coronary intervention in refractory unstable angina. Lancet 1997; 349: 1429-1435.","journal-title":"Lancet"},{"key":"388387_CR21","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","volume":"96","author":"The RESTORE Investigators.","year":"1997","unstructured":"The RESTORE Investigators. Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. Circulation 1997; 96: 1445-1453.","journal-title":"Circulation"},{"key":"388387_CR22","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1056\/NEJM199805213382103","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management","year":"1998","unstructured":"Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. Acomparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-1505.","journal-title":"N Engl J Med"},{"key":"388387_CR23","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJM199805213382102","volume":"338","author":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable SignsSymptoms","year":"1998","unstructured":"Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb\/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998; 338: 1488-1497.","journal-title":"N Engl J Med"},{"key":"388387_CR24","doi-asserted-by":"crossref","first-page":"S570","DOI":"10.1053\/hj.1999.v138.a102298","volume":"138","author":"HD. White","year":"1999","unstructured":"White HD. Newer antiplatelet agents in acute coronary syndromes. Am Heart J 1999; 138: S570-576.","journal-title":"Am Heart J"},{"key":"388387_CR25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199808133390704","volume":"339","author":"The PURSUIT Trial Investigators.","year":"1998","unstructured":"The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb\/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet glycoprotein IIb\/IIIa in unstable angina: Receptor suppression using integrilin therapy. N Engl J Med 1998; 339: 436-443.","journal-title":"N Engl J Med"},{"key":"388387_CR26","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1161\/01.CIR.97.24.2386","volume":"97","author":"The PARAGON Investigators.","year":"1998","unstructured":"The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb\/IIIa inhibitor), heparin, or both in unstable angina. Platelet IIb\/IIIa antagonism for the reduction of acute coronary syndrome events in a global organization network. Circulation 1998; 97: 2386-2395.","journal-title":"Circulation"},{"key":"388387_CR27","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0140-6736(99)11179-6","volume":"355","author":"The SYMPHONY Investigators.","year":"2000","unstructured":"The SYMPHONY Investigators. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial. Sibrafiban versus aspirin to yield maximum protection from ischemic heart events post-acute coronary syndromes. Lancet 2000; 355: 337-345.","journal-title":"Lancet"},{"key":"388387_CR28","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/01.CIR.102.2.149","volume":"102","author":"CP Cannon","year":"2000","unstructured":"Cannon CP, McCabe CH, Wilcox RG, et al. Oral glycoprotein IIb\/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 2000; 102: 149-156.","journal-title":"Circulation"},{"key":"388387_CR29","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","volume":"339","author":"MB Leon","year":"1998","unstructured":"Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronaryartery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339: 1665-1671.","journal-title":"N Engl J Med"},{"key":"388387_CR30","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","volume":"98","author":"ME Bertrand","year":"1998","unstructured":"Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998; 98: 1597-1603.","journal-title":"Circulation"},{"key":"388387_CR31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","volume":"334","author":"A Schomig","year":"1996","unstructured":"Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-1089.","journal-title":"N Engl J Med"},{"key":"388387_CR32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1161\/01.CIR.93.2.215","volume":"93","author":"P Hall","year":"1996","unstructured":"Hall P, Nakamura S, Maiello L, et al. A randomized comparison of combined ticlopidine and aspirin therapy versus aspirin therapy alone after successful intravascular ultrasound-guided stent implantation. Circulation 1996; 93: 215-222.","journal-title":"Circulation"},{"key":"388387_CR33","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1161\/01.CIR.94.7.1519","volume":"94","author":"GJ Karrillon","year":"1996","unstructured":"Karrillon GJ, Morice MC, Benveniste E, et al. Intracoronary stent implantation without ultrasound guidance and with replacement of conventional anticoagulation by antiplatelet therapy. 30-day clinical outcome of the French Multicenter Registry. Circulation 1996; 94: 1519-1527.","journal-title":"Circulation"},{"key":"388387_CR34","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","volume":"98","author":"P Urban","year":"1998","unstructured":"Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98: 2126-2132.","journal-title":"Circulation"},{"key":"388387_CR35","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/01.CIR.99.18.2364","volume":"99","author":"I Moussa","year":"1999","unstructured":"Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99: 2364-2366.","journal-title":"Circulation"},{"key":"388387_CR36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/01.CIR.82.1.17","volume":"82","author":"F Balsano","year":"1990","unstructured":"Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation 1990; 82: 17-26.","journal-title":"Circulation"},{"key":"388387_CR37","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/euhj.1999.1874","volume":"21","author":"JM Cruz-Fernandez","year":"2000","unstructured":"Cruz-Fernandez JM, Lopez-Bescos L, Garcia-Dorado D, et al. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. Eur Heart J 2000; 21: 457-465.","journal-title":"Eur Heart J"},{"key":"388387_CR38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(00)02427-2","volume":"356","author":"L Wallentin","year":"2000","unstructured":"Wallentin L, Lagerqvist B, Husted S, et al. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: The FRISC II invasive randomised trial. FRISC II Investigators. Fast revascularisation during instability in coronary artery disease. Lancet 2000; 356: 9-16.","journal-title":"Lancet"},{"key":"388387_CR39","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.100.20.2045","volume":"100","author":"E Boersma","year":"1999","unstructured":"Boersma E, Akkerhuis KM, Theroux P, Califf RM, Topol EJ, Simoons ML. Platelet glycoprotein IIb\/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999; 100: 2045-2048.","journal-title":"Circulation"},{"key":"388387_CR40","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","volume":"36","author":"E Braunwald","year":"2000","unstructured":"Braunwald E, Antman EM, Beasley JW, et al. ACC\/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology\/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). J Am Coll Cardiol 2000; 36: 970-1062.","journal-title":"J Am Coll Cardiol"},{"key":"388387_CR41","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1053\/euhj.2000.2301","volume":"21","author":"ME Bertrand","year":"2000","unstructured":"Bertrand ME, Simoons ML, Fox KA, et al. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406-1432.","journal-title":"Eur Heart J"},{"key":"388387_CR42","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S0735-1097(98)00130-2","volume":"31","author":"JS Mandak","year":"1998","unstructured":"Mandak JS, Blankenship JC, Gardner LH, et al. Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to minimize platelet aggregation and coronary thrombosis. J Am Coll Cardiol 1998; 31: 1518-1524.","journal-title":"J Am Coll Cardiol"},{"key":"388387_CR43","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0003-4975(00)01343-6","volume":"70","author":"AM Lincoff","year":"2000","unstructured":"Lincoff AM, LeNarz LA, Despotis GJ, et al. Abciximab and bleeding during coronary surgery: Results from the EPILOG and EPISTENT trials. Improve long-term outcome with abciximab GP IIb\/IIIa blockade. Evaluation of platelet IIb\/IIIa inhibition in STENTing. Ann Thorac Surg 2000; 70: 516-526.","journal-title":"Ann Thorac Surg"},{"key":"388387_CR44","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1056\/NEJM200005043421803","volume":"342","author":"WW O'Neill","year":"2000","unstructured":"O'Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization.EXCITETrial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events. N Engl J Med 2000; 342: 1316-1324.","journal-title":"N Engl J Med"},{"issue":"A10","key":"388387_CR45","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0002-9149(99)00778-X","volume":"85","author":"MB Holmes","year":"2000","unstructured":"Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: An OPUS-TIMI 16 substudy. Orbofiban in patients with unstable coronary syndromes. Thrombolysis in myocardial infarction. Am J Cardiol 2000; 85(A10): 491-493.","journal-title":"Am J Cardiol"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1013393607384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1013393607384\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1013393607384.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:22:50Z","timestamp":1751052170000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1013393607384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,9]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2001,9]]}},"alternative-id":["388387"],"URL":"https:\/\/doi.org\/10.1023\/a:1013393607384","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2001,9]]}}}